

References

I-185

1. Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. *Eur J Haematol*. 2017;98:425–434.
2. Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. *The Lancet*. 2018;19:240-48.
3. Compendium™. Inotuzumab Ozogamicin. 2019. National Comprehensive Cancer Network (NCCN).
4. MICROMEDEX®SOLUTIONS Compendia. 2019. Inotuzumab Ozogamicin.
5. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Inotuzumab Ozogamicin. 2019.
6. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.
7. Yurkiewicz IR, Muffy L, Liedtke M. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. *Drug Design, Development And Therapy*. 2018;12:2293-2300.
8. Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. *Cancer*. 2018;124(8):1722-1732.
9. Besponsa (inotuzumab ozogamicin) injection, powder, lyophilized, for solution [package insert]. Wyeth Pharmaceuticals. Philadelphia, PA. Revised 03/2018.